4Suppliers
10Customers
3Debt Items
0Related Chains

Zeo ScientifiX, Inc. Suppliers

TickerNameConfidenceEvidence
REGEN-THERAPY REGEN-THERAPY 92% pursuant to which ZEO is expected to be positioned as the core supplier of advanced biologic therapeutics to be incorporated into the next-generation regenerative offerings on Regen's clinical platform
ONE-SUPPLIER ONE-SUPPLIER 90% During the fiscal year ended October 31, 2024, the Company purchased the tissue raw material used in manufacturing of its products from one supplier in the amount of $ 135,000
THIRD-PARTY-CONTRACT-MANUFACTURER THIRD-PARTY-CONTRACT-MANUFACTURER 90% Company entered into an exclusive supply agreement with a third-party contract manufacturer in connection with the manufacturing and processing of certain biological products
TWO-SUPPLIERS TWO-SUPPLIERS 90% During the fiscal year ended October 31, 2023, the Company purchased the tissue raw material used in manufacturing of its products from two suppliers, of which each accounted for approximately $ 113,…

Zeo ScientifiX, Inc. Customers

TickerNameConfidenceEvidence
ANOTHER-LARGE-DISTRIBUTOR ANOTHER-LARGE-DISTRIBUTOR 90% Company sold products and services totaling approximately $ 106,000 ( 11.3 % ) to another large distributor
ANOTHER-LARGE-MEDICAL-PRACTICE-GROUP-AND-DISTRIB ANOTHER-LARGE-MEDICAL-PRACTICE-GROUP-AND-DISTRIB 90% Company sold products and services totaling approximately $ 169,000 ( 11.7 % ) to another large medical practice group and distributor
INDIVIDUAL-MEDICAL-PRACTICE INDIVIDUAL-MEDICAL-PRACTICE 90% During the year ended October 31, 2023, the Company sold products and services totaling approximately $ 460,000 ( 10.1 % ) to an individual medical practice
LARGE-DISTRIBUTOR LARGE-DISTRIBUTOR 90% Company sold products and services totaling approximately $ 108,000 ( 11.5 % ) to a large distributor
LARGE-MEDICAL-PRACTICE-GROUP-AND-DISTRIBUTOR LARGE-MEDICAL-PRACTICE-GROUP-AND-DISTRIBUTOR 90% Company sold products and services totaling approximately $ 237,000 ( 16.4 % ) to a large medical practice group and distributor
EXOTROPIN EXOTROPIN 80% Company is entitled to receive commissions on the net sales value of Exotropin products sold to pre-approved customers introduced by the Company
BESPOKE-TRICYCLES-INC BESPOKE-TRICYCLES-INC 62% nc., a Nevada corporation, and its subsidiaries consolidated as a combined entity. ii PART I Item 1. Business. Overview We are a clinical-stage biopharmaceutical company principally focusing on the d…
EXOTROPIN-LLC EXOTROPIN-LLC 62% nc., a Nevada corporation, and its subsidiaries consolidated as a combined entity. ii PART I Item 1. Business. Overview We are a clinical-stage biopharmaceutical company principally focusing on the d…
FORMERLY-ORGANICELL-REGENERATIVE-MEDICINE-INC FORMERLY-ORGANICELL-REGENERATIVE-MEDICINE-INC 62% 0 Fair value of vested options issued - - 953,000 - 953,000 Fair value of vested warrants issued - - 2,450,000 - 2,450,000 Net loss - - - ( 4,705,000 ) ( 4,705,000 ) Balance October 31, 2024 6,344,81…
ORGANICELL-REGENERATIVE-MEDICINE-INC ORGANICELL-REGENERATIVE-MEDICINE-INC 62% nc., a Nevada corporation, and its subsidiaries consolidated as a combined entity. ii PART I Item 1. Business. Overview We are a clinical-stage biopharmaceutical company principally focusing on the d…

Zeo ScientifiX, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
ZEOX-DEBT-13747 Warrants outstanding: 2.86 90% xbrl warrant detail from xbrl 2025-10-31.
ZEOX-DEBT Debt stack $349,000 90% Market cache reports total debt of $349,000.
ZEOX-DEBT-13748 Xbrl Convertible 90% xbrl convertible detail from xbrl 2023-02-10.

Zeo ScientifiX, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Zeo ScientifiX, Inc..

Zeo ScientifiX, Inc. Ownership

No ownership data on recordNo major institutional ownership relationships found in our database for Zeo ScientifiX, Inc..

Zeo ScientifiX, Inc. Extended Supply Chain Network

No secondary connectionsNo correlated companies found through shared supply chain relationships.